{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T10:54:36Z","timestamp":1774954476080,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,1,10]],"date-time":"2017-01-10T00:00:00Z","timestamp":1484006400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s00345-016-1995-z","type":"journal-article","created":{"date-parts":[[2017,1,10]],"date-time":"2017-01-10T09:17:25Z","timestamp":1484039845000},"page":"1401-1407","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review"],"prefix":"10.1007","volume":"35","author":[{"name":"For the Young Academic Urologists Urothelial Carcinoma Group of the European Association of Urology","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atiqullah","family":"Aziz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakub","family":"Dobruch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kees","family":"Hendricksen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis A.","family":"Kluth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aidan","family":"Noon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Rink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Roghmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Seiler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Gontero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wassim","family":"Kassouf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evanguelos","family":"Xylinas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,1,10]]},"reference":[{"key":"1995_CR1","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.eururo.2013.03.032","volume":"63","author":"M Roupret","year":"2013","unstructured":"Roupret M, Babjuk M, Comperat E et al (2013) European guidelines on upper tract urothelial carcinomas: 2013 update. Eur Urol 63:1059\u20131071","journal-title":"Eur Urol"},{"key":"1995_CR2","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/cncr.24135","volume":"115","author":"V Margulis","year":"2009","unstructured":"Margulis V, Shariat SF, Matin SF et al (2009) Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 115:1224\u20131233","journal-title":"Cancer"},{"key":"1995_CR3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.urology.2006.10.014","volume":"69","author":"T Kondo","year":"2007","unstructured":"Kondo T, Nakazawa H, Ito F, Hashimoto Y, Toma H, Tanabe K (2007) Primary site and incidence of lymph node metastases in urothelial carcinoma of upper urinary tract. Urology 69:265\u2013269","journal-title":"Urology"},{"key":"1995_CR4","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","volume":"48","author":"Advanced Bladder Cancer Meta-analysis C","year":"2005","unstructured":"Advanced Bladder Cancer Meta-analysis C (2005) Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 48:202\u2013205 (discussion 05-6)","journal-title":"Eur Urol"},{"key":"1995_CR5","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.eururo.2013.08.033","volume":"66","author":"JJ Leow","year":"2014","unstructured":"Leow JJ, Martin-Doyle W, Rajagopal PS et al (2014) Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol 66:42\u201354","journal-title":"Eur Urol"},{"key":"1995_CR6","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.eururo.2014.03.003","volume":"66","author":"JJ Leow","year":"2014","unstructured":"Leow JJ, Martin-Doyle W, Fay AP, Choueiri TK, Chang SL, Bellmunt J (2014) A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma. Eur Urol 66:529\u2013541","journal-title":"Eur Urol"},{"key":"1995_CR7","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1053\/j.seminoncol.2012.08.007","volume":"39","author":"J Bellmunt","year":"2012","unstructured":"Bellmunt J, Petrylak DP (2012) New therapeutic challenges in advanced bladder cancer. Semin Oncol 39:598\u2013607","journal-title":"Semin Oncol"},{"key":"1995_CR8","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.eururo.2008.06.013","volume":"55","author":"JM Oers van","year":"2009","unstructured":"van Oers JM, Zwarthoff EC, Rehman I et al (2009) FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. Eur Urol 55:650\u2013657","journal-title":"Eur Urol"},{"key":"1995_CR9","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.eururo.2010.06.029","volume":"58","author":"MG Kaag","year":"2010","unstructured":"Kaag MG, O\u2019Malley RL, O\u2019Malley P et al (2010) Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy. Eur Urol 58:581\u2013587","journal-title":"Eur Urol"},{"key":"1995_CR10","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1464-410X.2012.11649.x","volume":"112","author":"E Xylinas","year":"2013","unstructured":"Xylinas E, Rink M, Margulis V et al (2013) Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomy. BJU Int 112:453\u2013461","journal-title":"BJU Int"},{"key":"1995_CR11","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00345-012-0960-8","volume":"31","author":"J Cordier","year":"2013","unstructured":"Cordier J, Sonpavde G, Stief CG, Tilki D (2013) Oncologic outcomes obtained after neoadjuvant and adjuvant chemotherapy for the treatment of urothelial carcinomas of the upper urinary tract: a review. World J Urol 31:77\u201382","journal-title":"World J Urol"},{"key":"1995_CR12","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.eururo.2011.03.023","volume":"59","author":"A Stenzl","year":"2011","unstructured":"Stenzl A, Cowan NC, De Santis M et al (2011) Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 59:1009\u20131018","journal-title":"Eur Urol"},{"key":"1995_CR13","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.urolonc.2010.07.016","volume":"31","author":"F Audenet","year":"2013","unstructured":"Audenet F, Yates DR, Cussenot O, Roupret M (2013) The role of chemotherapy in the treatment of urothelial cell carcinoma of the upper urinary tract (UUT-UCC). Urol Oncol 31:407\u2013413","journal-title":"Urol Oncol"},{"key":"1995_CR14","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s11934-013-0307-z","volume":"14","author":"BA Gayed","year":"2013","unstructured":"Gayed BA, Thoreson GR, Margulis V (2013) The role of systemic chemotherapy in management of upper tract urothelial cancer. Curr Urol Rep 14:94\u2013101","journal-title":"Curr Urol Rep"},{"key":"1995_CR15","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/j.1464-410X.2009.08821.x","volume":"105","author":"M Waldert","year":"2010","unstructured":"Waldert M, Karakiewicz PI, Raman JD et al (2010) A delay in radical nephroureterectomy can lead to upstaging. BJU Int 105:812\u2013817","journal-title":"BJU Int"},{"key":"1995_CR16","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000282755","volume":"55","author":"M Igawa","year":"1995","unstructured":"Igawa M, Urakami S, Shiina H et al (1995) Neoadjuvant chemotherapy for locally advanced urothelial cancer of the upper urinary tract. Urol Int 55:74\u201377","journal-title":"Urol Int"},{"key":"1995_CR17","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1002\/cncr.25050","volume":"116","author":"SF Matin","year":"2010","unstructured":"Matin SF, Margulis V, Kamat A et al (2010) Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer 116:3127\u20133134","journal-title":"Cancer"},{"key":"1995_CR18","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.28655","volume":"120","author":"S Porten","year":"2014","unstructured":"Porten S, Siefker-Radtke AO, Xiao L et al (2014) Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer 120:1794\u20131799","journal-title":"Cancer"},{"key":"1995_CR19","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1111\/j.1464-410X.2011.10075.x","volume":"108","author":"RF Youssef","year":"2011","unstructured":"Youssef RF, Shariat SF, Lotan Y et al (2011) Upper urinary tract urothelial carcinoma with loco-regional nodal metastases: insights from the Upper Tract Urothelial Carcinoma Collaboration. BJU Int 108:1286\u20131291","journal-title":"BJU Int"},{"key":"1995_CR20","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.ijrobp.2014.01.001","volume":"88","author":"PJ Gray","year":"2014","unstructured":"Gray PJ, Lin CC, Jemal A et al (2014) Clinical\u2013pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base. Int J Radiat Oncol Biol Phys 88:1048\u20131056","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1995_CR21","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1200\/JCO.2004.09.043","volume":"22","author":"A Bamias","year":"2004","unstructured":"Bamias A, Deliveliotis C, Fountzilas G et al (2004) Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: a study by the Hellenic Cooperative Oncology Group. J Clin Oncol 22:2150\u20132154","journal-title":"J Clin Oncol"},{"key":"1995_CR22","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.juro.2009.05.011","volume":"182","author":"NJ Hellenthal","year":"2009","unstructured":"Hellenthal NJ, Shariat SF, Margulis V et al (2009) Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration. J Urol 182:900\u2013906","journal-title":"J Urol"},{"key":"1995_CR23","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00345-011-0775-z","volume":"30","author":"A Kawashima","year":"2012","unstructured":"Kawashima A, Nakai Y, Nakayama M et al (2012) The result of adjuvant chemotherapy for localized pT3 upper urinary tract carcinoma in a multi-institutional study. World J Urol 30:701\u2013706","journal-title":"World J Urol"},{"key":"1995_CR24","doi-asserted-by":"crossref","first-page":"686","DOI":"10.7150\/jca.7326","volume":"4","author":"TS Kim","year":"2013","unstructured":"Kim TS, Oh JH, Rhew HY (2013) The efficacy of adjuvant chemotherapy for locally advanced upper tract urothelial cell carcinoma. J Cancer 4:686\u2013690","journal-title":"J Cancer"},{"key":"1995_CR25","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.urology.2006.01.053","volume":"68","author":"C Kwak","year":"2006","unstructured":"Kwak C, Lee SE, Jeong IG, Ku JH (2006) Adjuvant systemic chemotherapy in the treatment of patients with invasive transitional cell carcinoma of the upper urinary tract. Urology 68:53\u201357","journal-title":"Urology"},{"key":"1995_CR26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000092930","volume":"77","author":"SE Lee","year":"2006","unstructured":"Lee SE, Byun SS, Park YH, Chang IH, Kim YJ, Hong SK (2006) Adjuvant chemotherapy in the management of pT3N0M0 transitional cell carcinoma of the upper urinary tract. Urol Int 77:22\u201326","journal-title":"Urol Int"},{"key":"1995_CR27","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.juro.2014.10.022","volume":"193","author":"S Shirotake","year":"2015","unstructured":"Shirotake S, Kikuchi E, Tanaka N et al (2015) Impact of an adjuvant chemotherapeutic regimen on the clinical outcome in high risk patients with upper tract urothelial carcinoma: a Japanese multi-institution experience. J Urol 193:1122\u20131128","journal-title":"J Urol"},{"key":"1995_CR28","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/j.1442-2042.2008.02114.x","volume":"15","author":"N Soga","year":"2008","unstructured":"Soga N, Arima K, Sugimura Y (2008) Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma. Int J Urol 15:800\u2013803","journal-title":"Int J Urol"},{"key":"1995_CR29","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.1002\/cncr.26172","volume":"117","author":"M Vassilakopoulou","year":"2011","unstructured":"Vassilakopoulou M, de la Motte Rouge T, Colin P et al (2011) Outcomes after adjuvant chemotherapy in the treatment of high-risk urothelial carcinoma of the upper urinary tract (UUT-UC): results from a large multicenter collaborative study. Cancer 117:5500\u20135508","journal-title":"Cancer"},{"key":"1995_CR30","doi-asserted-by":"crossref","first-page":"31.e17","DOI":"10.1016\/j.urolonc.2012.11.014","volume":"32","author":"FA Yafi","year":"2014","unstructured":"Yafi FA, Tanguay S, Rendon R et al (2014) Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: assessment of adequate renal function and influence on outcome. Urol Oncol 32:31.e17\u201331.e24","journal-title":"Urol Oncol"},{"key":"1995_CR31","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/bju.12801","volume":"116","author":"I Lucca","year":"2015","unstructured":"Lucca I, Kassouf W, Kapoor A et al (2015) The role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma following radical nephroureterectomy: a retrospective study. BJU Int 116:72\u201378","journal-title":"BJU Int"},{"key":"1995_CR32","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/j.1464-410X.2012.11413.x","volume":"110","author":"AJ Birtle","year":"2012","unstructured":"Birtle AJ, Lewis R, Johnson M, Hall E, Group PTM (2012) Time to define an international standard of postoperative care for resected upper urinary tract transitional cell carcinoma (TCC)\u2014opening of the peri-operative chemotherapy versus surveillance in upper tract urothelial cancer (POUT) Trial. BJU Int 110:919\u2013921","journal-title":"BJU Int"},{"key":"1995_CR33","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/cncr.22588","volume":"109","author":"BA Inman","year":"2007","unstructured":"Inman BA, Sebo TJ, Frigola X et al (2007) PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer 109:1499\u20131505","journal-title":"Cancer"},{"key":"1995_CR34","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372:2018\u20132028","journal-title":"N Engl J Med"},{"key":"1995_CR35","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320\u2013330","journal-title":"N Engl J Med"},{"key":"1995_CR36","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF et al (2015) Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1803\u20131813","journal-title":"N Engl J Med"},{"key":"1995_CR37","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.4049\/jimmunol.170.3.1257","volume":"170","author":"JA Brown","year":"2003","unstructured":"Brown JA, Dorfman DM, Ma FR et al (2003) Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 170:1257\u20131266","journal-title":"J Immunol"},{"key":"1995_CR38","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","volume":"2","author":"Y Latchman","year":"2001","unstructured":"Latchman Y, Wood CR, Chernova T et al (2001) PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2:261\u2013268","journal-title":"Nat Immunol"},{"key":"1995_CR39","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg JE, Hoffman-Censits J, Powles T et al (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387:1909\u20131920","journal-title":"Lancet"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00345-016-1995-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-016-1995-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-016-1995-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,9,4]],"date-time":"2017-09-04T02:03:48Z","timestamp":1504490628000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00345-016-1995-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,10]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["1995"],"URL":"https:\/\/doi.org\/10.1007\/s00345-016-1995-z","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,10]]}}}